Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 95c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of $0.46, $0.95 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.3 million versus the consensus estimate of $50.49 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance